e from operations 28,650,649 8,410,737
Non-operating income (expenses)
Interest expenses (125,201) (142,442)
Subsidy income 100,792 328,697
Other expense (63,519) (17,427)
Stock based compensation - make
good provision (9,838,354) --
Total non-operating expenses (9,926,282) 168,828
Net income 18,724,367 8,579,565
Other comprehensive item
Foreign currency translation gain 3,017,271 1,694,926
Comprehensive Income $21,741,638 $10,274,491
Net Income 18,724,367 8,579,565
Deemed dividend to preferred
stockholders 863,014 3,398,534
Net income available to common
stockholders 17,861,353 5,181,031
Basic and diluted weighted average
shares outstanding
Basic 25,889,748 24,238,107
Diluted 32,877,570 25,145,122
Basic and diluted net earnings per
share available to common stockholders
Basic $0.69 $0.21
Diluted $0.54 $0.21
CHINA BIO ENERGY HOLDING GROUP CO., LTD. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOW
For The Year Ended
December 31, December 31,
2008 2007
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income
'/>"/>SOURCE China Bio Energy Holdings Group Copyright©2009 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 Related biology technology :1.
aTyr Pharma to Present at ChinaBio(R) Investor Forum in Hong Kong2.
Niusule Biotech Corp. Formally Establishes a New Venture to Import and Sell Health Foods in the Peoples Republic of China3.
China-Biotics, Inc. Appoints New Chief Financial Officer4.
China Medical Technologies Senior Management Purchased Company Shares5.
China Bio-Immunity Corporation - Rabies Vaccine Recall6.
China Medicine to Participate in 2009 Natural Products Expo West Trade Show7.
China Sky One Medical, Inc. Signs Exclusive Distribution Agreement with Shaanxi Buchang Group for Naftopidil Dispersible Tablets8.
Frontage Laboratories Continues to Grow Its China Business and Add Corporate Financial, Regulatory and Clinical Pharmacology Talent9.
Dow AgroSciences, China National Rice Research Institute Announce Collaboration on Rice Research10.
China Biologic Products High-Purity Human Albumin Research and Development Project to be Listed in the National Torch Plan11.
OriGene Technologies, Inc. Establishes High Throughput Monoclonal Antibody Production Outsourcing Center in China